- Home
- EDTK vs CLRB Comparison
EDTK vs CLRB Comparison
Compare EDTK & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | CLRB |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDTK | CLRB |
|---|---|---|
| Price | $0.90 | $3.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.8K | ★ 34.5K |
| Earning Date | 01-16-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $893,690.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $2.45 |
| 52 Week High | $1.18 | $20.60 |
Technical Indicators
Market Signals| Indicator | EDTK | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 50.18 |
| Support Level | $0.86 | $3.14 |
| Resistance Level | $1.03 | $3.42 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 18.11 | 54.24 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.